Simplification of HAART therapy on ambulatory HIV patients in Malaysia: a randomized controlled trial
Pharm. pract. (Granada, Internet)
; 14(4): 0-0, oct.-dic. 2016. tab
Artículo
en Inglés
| IBECS
| ID: ibc-158878
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Objective:
Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV.Methods:
HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months.Result:
Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group.Conclusion:
Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients (AU)RESUMEN
No disponible
Texto completo:
Disponible
Colección:
Bases de datos nacionales
/
España
Contexto en salud:
Agenda de Salud Sostenible para las Américas
/
ODS3 - Salud y Bienestar
Problema de salud:
Objetivo 9: Enfermedades no transmisibles y salud mental
/
Meta 3.3: Poner fin a las enfermedades desatendidas y detener enfermedades transmisibles
Base de datos:
IBECS
Asunto principal:
Calidad de Vida
/
Síndrome de Inmunodeficiencia Adquirida
/
Recuento de Linfocito CD4
/
Antirretrovirales
/
Cumplimiento de la Medicación
/
Combinación Elvitegravir, Cobicistat, Emtricitabina y Fumarato de Tenofovir Disoproxil
/
Combinación Emtricitabina, Rilpivirina y Tenofovir
/
Síndromes de Inmunodeficiencia
Tipo de estudio:
Ensayo clínico controlado
Aspecto:
Preferencia del paciente
Límite:
Femenino
/
Humanos
/
Masculino
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Pharm. pract. (Granada, Internet)
Año:
2016
Tipo del documento:
Artículo
Institución/País de afiliación:
Hospital Sungai Buloh/Malaysia
/
National University of Malaysia/Malaysia